MUMBAI: Eris Lifesciences is set to beat stronger in the cardiometabolic space with the appointment of Murari Ranganathan as president, cardiometabolic business. Stepping into the Mumbai office, he will spearhead the company’s Anti-Diabetes and Cardiology divisions, two of Eris’ flagship verticals.

Eris Lifesciences chairman and managing director Amit Bakshi said, "Murari’s expertise will be invaluable in strengthening our position in the cardiometabolic segment. We’re thrilled to have him on board and look forward to the milestones ahead."

On his appointment, Ranganathan said, "Eris Lifesciences is the youngest player among the top 20 pharmaceutical companies in India, and its dynamic, entrepreneurial culture is truly inspiring. I look forward to working with the team to set new benchmarks in disease management and patient care."

Ranganathan brings over two decades of industry experience, having previously served as commercial director at Abbott India Ltd, where he led women’s health, metabolics, and international business. His career spans leadership roles at Baxter, Novo Nordisk, and Torrent Pharma, and he holds a Postgraduate Diploma in Marketing from St. Joseph College of Business Administration, Bangalore.

With this strategic move, Eris Lifesciences is set to fortify its presence in one of India’s fastest-growing healthcare segments, keeping its commitment to innovation and patient well-being at the heart of its expansion.